Log In      Register Advertisement
Managed Care


August 2015

Makers of this expensive new cystic fibrosis medication manage to sidestep controversy. Health plans may not be as lucky as they weigh cost against value.

Ed Silverman
The search is on for ways to pay for health care that make value more important than volume.
Peter Wehrwein

Yes, it failed to uproot the volume and intensity incentives of fee-for-service medicine. But P4P deserves credit for getting the world ready for today’s value-based payment.

Frank Diamond

Paying for care by the episodes may be the shortest path to value-based care. But administration is tricky, and early results raise questions about the savings achieved.

Jan Greene

Of all the “value-based” provider payment methodologies, this one’s the classic. And it may be mounting a comeback.

Timothy Kelley

Without shared risk, shared savings might not be strong enough medicine for what ails American health care.

Peter Wehrwein

Ruling in same-sex marriage case extends insurance coverage, but problems with discrimination and lack of access persist.

Joseph Burns

Legislation & Regulation

One of the purposes of health care reform was to create more competition, and the recent spate of acquisitions works against that.

Richard Mark Kirkner
Medication Management

This knowledge won’t come cheap, as the system braces for new agents that could add another $42 billion to the nation’s drug bill.

Thomas Reinke
Medical Device Monitor
Katherine T. Adams
Tomorrow's Medicine

The combination of a neprilysin inhibitor and an ARB rescued neprilysin inhibition from obscurity.

Thomas Morrow, MD